Prenetics Global CEO Touts IM8 Breakout Growth, Guides $180M-$200M Revenue at Conference

Prenetics Global (NASDAQ:PRE) CEO and co-founder Danny Yeung told investors the institution delivered what helium described arsenic a “breakout maturation story” successful 2025, driven by the accelerated enlargement of its IM8 direct-to-consumer supplements concern and a broader strategical displacement to absorption connected that brand.

Yeung said Prenetics generated astir $92 cardinal successful full-year 2025 revenue, inclusive of aggregate concern units. He attributed the results mostly to IM8, which helium said reached $120 cardinal successful yearly recurring gross (ARR) successful its archetypal afloat twelvemonth of operations and ended 2025 astatine 63% gross margins.

→ Forget Chipmakers: Walmart and Target Are the Real AI Plays

According to Yeung, IM8 launched successful December 2024 and scaled quickly. He said the brand’s first-month gross was astir $581,000 and grew to $10 cardinal successful monthly revenue by December 2025. He characterized the maturation arsenic unusually accelerated for the vitamins and supplements category.

Yeung said Prenetics has divested non-core assets to ore connected IM8 and believes it present has “a precise wide roadmap to profitability by Q4 of 2027.” He besides emphasized the company’s liquidity position, stating Prenetics has astir $160 cardinal successful liquid assets and zero debt.

→ Expedia Stock Turns Volatile After Rally. Where Does It Go Next?

He outlined respective transactions completed arsenic portion of the portfolio simplification:

• ACT was sold successful October for $72 cardinal successful cash, and Yeung said Prenetics received astir $46 million of that amount.

• Europa was sold successful an all-stock transaction for up to $13 million.

• The institution sold its full involvement successful Insighta to Tencent for $70 cardinal successful cash, which Yeung said occurred “last month.”

He said the divestments were driven by IM8’s maturation accidental and management’s presumption that superior could beryllium deployed much efficaciously to grow the IM8 business.

→ The SkyWater Deal: IonQ's Bid for Quantum Supremacy

Yeung said IM8 ships to 31 countries and has been planetary from the start. He stated the U.S. represents astir 40% of the business, followed by Canada, the U.K., Australia, and Singapore. He besides said that successful 2025 IM8 generated astir $60 million successful revenue, with astir $24 million coming from the U.S., and argued the U.S. marketplace unsocial could enactment $150 cardinal to $200 million successful revenue.

Discussing the lawsuit profile, Yeung said IM8 is not lone for athletes. He described the emblematic lawsuit arsenic 30 to 60 years old, successful the top 10% of household incomes, and looking for a “clean,” “third-party tested,” U.S.-made merchandise without the request to negociate aggregate pills.